The Big Debate: Pan-Antifibrotics, Fact or Fiction? Dissecting Mechanisms & Organ Specificity & Strategies for Cross-Tissue Success
Time: 2:00 pm - 4:00 pm
day: Pre-Conference Day
Details:
As interest grows in developing antifibrotics with cross-indication potential, this workshop critically examines whether a true “pan-antifibrotic” is biologically and clinically feasible. Through real-world data, mechanistic comparisons, and forward-looking trial design strategies, we’ll explore what it would take to deliver a truly universal fibrosismodifying
therapy.
This workshop will gather experts to discuss:
- Reviewing trials of known antifibrotic targets (e.g., LOXL2, galectin-3, autotaxin, integrins) and why translation across organs often fails
- Clarifying what pan-antifibrotic really means, is it shared MoA, cross-organ signal, or a generalized fibrosis resolution mechanism?
- How to design development programs (e.g., patient populations, biomarkers, endpoints) to test and support pan-organ antifibrotic claims in Phase 2 and beyond.
